1840966-49-5

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-4-(2-(furan-3-yl)ethyl)-2-hydroxy-3,4,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-1(4H)-one is used as a building block for the synthesis of pharmaceuticals due to its unique structural features and potential pharmacological and biological activities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-4-(2-(furan-3-yl)ethyl)-2-hydroxy-3,4,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-1(4H)-one is used as a versatile compound for chemical reactions and modifications, contributing to the development of new bioactive molecules.
Used in Organic Synthesis:
(S)-4-(2-(furan-3-yl)ethyl)-2-hydroxy-3,4,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-1(4H)-one is also utilized in organic synthesis, where its aromatic and hydroxyl groups allow for a wide range of chemical reactions and modifications, making it a valuable component in creating diverse organic compounds.

Upstream product

• 23534-56-7 15,16-epoxy-9-hydroxy-7,13⁽¹⁶⁾,14-labdatrien-6-one 

Relevant academic research and scientific papers

Semisynthesis and inhibitory effects of solidagenone derivatives on TLR-mediated inflammatory responses

A series of nine derivatives (2–10) were prepared from the diterpene solidagenone (1) and their structures were elucidated by means of spectroscopic studies. Their ability to inhibit inflammatory responses elicited in peritoneal macrophages by TLR ligands was investigated. Compounds 5 and 6 showed significant anti-inflammatory effects, as they inhibited the protein expression of nitric oxide synthase (NOS-2), cyclooxygenase-2 (COX-2), and cytokine production (TNF-α, IL-6, and IL-12) induced by the ligand of TLR4, lipopolysaccharide (LPS), acting at the transcriptional level. Some structure–activity relationships were outlined. Compound 5 was selected as a representative compound and molecular mechanisms involved in its biological activity were investigated. Inhibition of NF-B and p38 signaling seems to be involved in the mechanism of action of compound 5. In addition, this compound also inhibited inflammatory responses mediated by ligands of TLR2 and TLR3 receptors. To rationalize the obtained results, molecular docking and molecular dynamic studies were carried out on TLR4. All these data indicate that solidagenone derivative 5 might be used for the design of new anti-inflammatory agents.